NCT05162053View on ClinicalTrials.gov

PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers

PHASE1CompletedINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

December 9, 2021

Primary Completion Date

November 3, 2022

Study Completion Date

November 3, 2022

Conditions
Acute Coronary Syndrome
Interventions
DRUG

vicagrel Capsules

Oral administration for 7 days under fasting

DRUG

Clopidogrel Tablets

Oral administration for 7 days under fasting

Trial Locations (3)

66212

Altasciences, Kansas City, Kansas City

90630

Altasciences Clinical, Los Angeles, Los Angeles

130021

Phase I Clinical Research Center of The First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

Jiangsu vcare pharmaceutical technology co., LTD

INDUSTRY

NCT05162053 - PK/PD Study of Vicagrel and Clopidogrel in Healthy Subjects With Different CYP2C19 Metabolizers | Biotech Hunter | Biotech Hunter